Outcome of the meeting of the Board of Directors held on Wednesday, June 10, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The Board of Shukra Pharmaceuticals has approved seeking fresh shareholder approval for a preferential issue of 46,43,000 convertible equity warrants to the promoter group, valued at approximately Rs.16.51 crore. The original warrant issue was approved by shareholders at an EGM on November 1, 2025, and received BSE in-principle approval on January 9, 2026, but the allotment could not be completed within the time period prescribed under SEBI rules. Due to this delay, fresh shareholder approval is now required, and the warrant price has been revised upward from Rs.34 to Rs.35.56 per warrant based on a fresh pricing exercise. The warrants are being allotted to 5 promoter-group entities, with promoter shareholding rising marginally from 49.73% to 50.25% post-issue. An EGM has been scheduled for July 6, 2026, to seek this fresh approval.
This is largely a procedural re-approval with a small price increase (from Rs.34 to Rs.35.56 per warrant), which may slightly raise the dilution concern for non-promoter shareholders. Since the warrants are being issued to existing promoters, the promoter's stake will inch up by about 0.52%, marginally enhancing their control. The Rs.16.51 crore inflow comes at the cost of minor dilution upon conversion over the 18-month tenure.